Premium
RKI‐1447 suppresses colorectal carcinoma cell growth via disrupting cellular bioenergetics and mitochondrial dynamics
Author(s) -
Li Liyi,
Chen Qin,
Yu Yaojun,
Chen Hui,
Lu Mingdong,
Huang Yingpeng,
Li Pihong,
Chang Hong
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28965
Subject(s) - biology , cell growth , microbiology and biotechnology , mitochondrion , signal transduction , apoptosis , cancer research , biochemistry
Accumulated evidence suggested the importance of the Rho/Rho‐kinase (ROCK) signaling pathway in cancer proliferation and invasion. However, its role in colorectal carcinoma (CRC) is not well understood. This study evaluated the effect of ROCK signaling pathway on CRC behavior on the basis of a novel Rho/ROCK inhibitor RKI‐1447. Here, we found RKI‐1447 could drastically suppress HCT‐8 and HCT‐116 cell growth and promoted apoptosis. Our in vitro data indicated suppressed cytoskeletal dynamics induced by RKI‐1447 inhibition on mitochondrial respiration, which was evidenced by basal and maximal respiration rates, and ATP production. Simultaneously, cellular basal and maximal glycolytic rates, and glycolytic capacity were also reduced in response to RKI‐1447. Moreover, RKI‐1447 caused excessive reactive oxygen species generation and membrane depolarization as well as activated ER‐stress. We also demonstrated CHOP is essential for RKI‐1447 induced cell apoptosis. Finally, we proved inhibition of ROCK by RKI‐1447 could effectively inhibit CRC growth in vivo. Taken together, this study demonstrated that inhibition of ROCK signaling pathway by RKI‐1447 could suppress CRC via cytoskeleton associated mitochondrial dysfunction and cellular bioenergetics disruption. Our data suggest RKI‐1447 may be an attractive antitumor drug candidate for the treatment of CRC.